Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers

Xiyong Liu, Hang Zhang, Lily Lai, Xiaochen Wang, Sofia Loera, Lijun Xue, Huiyin He, Keqiang Zhang, Shuya Hu, Yasheng Huang, Rebecca A. Nelson, Bingsen Zhou, Lun Zhou, Peiguo Chu, Suzhan Zhang, Shu Zheng, Yun Yen

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The overexpression of RRM2 [RR (ribonucleotide reductase) small subunit M2] dramatically enhances the ability of the cancer cell to proliferate and to invade. To investigate further the relevance of RRM2 and CRCs (colorectal cancers), we correlated the expression of RRM2 with the clinical outcome of CRCs. A retrospective outcome study was conducted on CRCs collected from the COH [(City of Hope) National Medical Center, 217 cases] and ZJU (Zhejiang University, 220 cases). IHC (immunohistochemistry) was employed to determine the protein expression level of RRM2, and quantitative real-time PCR was employed to validate. Multivariate logistic analysis indicated that the adjusted ORs (odds ratios) of RRM2-high for distant metastases were 2.06 [95% CI (confidence interval), 1.01-4.30] and 5.89 (95% CI, 1.51-39.13) in the COH and ZJU sets respectively. The Kaplan-Meier analysis displayed that high expression of RRM2 had a negative impact on the OS (overall survival) and PFS (progress-free survival) of CRC in both sets significantly. The multivariate Cox analysis further demonstrated that HRs (hazard ratios) of RRM2-high for OS were 1.88 (95% CI, 1.03-3.36) and 2.06 (95% CI, 1.10-4.00) in the COH and ZJU sets respectively. Stratification analysis demonstrated that the HR of RRM2 dramatically increased to 12.22 (95% CI, 1.62-258.31) in the MMR (mismatch repair) gene-deficient subgroup in the COH set. Meanwhile, a real-time study demonstrated that down-regulation of RRM2 by siRNA (small interfering RNA) could significantly and specifically reduce the cell growth and adhesion ability in HT-29 and HCT-8 cells. Therefore RRM2 is an independent prognostic factor and predicts poor survival of CRCs. It is also a potential predictor for identifying good responders to chemotherapy for CRCs.

Original languageEnglish
Pages (from-to)567-578
Number of pages12
JournalClinical Science
Volume124
Issue number9
DOIs
Publication statusPublished - May 1 2013
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Biomarkers
Confidence Intervals
Aptitude
Multivariate Analysis
DNA Mismatch Repair
Time and Motion Studies
Kaplan-Meier Estimate
Cell Adhesion
Small Interfering RNA
ribonucleotide reductase M2
Real-Time Polymerase Chain Reaction
Down-Regulation
Retrospective Studies
Immunohistochemistry
Odds Ratio
Outcome Assessment (Health Care)
Neoplasm Metastasis
Drug Therapy
Growth

Keywords

  • Adenocarcinoma
  • Colon
  • Metastasis
  • Prognostic biomarker
  • Rectum
  • Ribonucleotide reductase
  • Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. / Liu, Xiyong; Zhang, Hang; Lai, Lily; Wang, Xiaochen; Loera, Sofia; Xue, Lijun; He, Huiyin; Zhang, Keqiang; Hu, Shuya; Huang, Yasheng; Nelson, Rebecca A.; Zhou, Bingsen; Zhou, Lun; Chu, Peiguo; Zhang, Suzhan; Zheng, Shu; Yen, Yun.

In: Clinical Science, Vol. 124, No. 9, 01.05.2013, p. 567-578.

Research output: Contribution to journalArticle

Liu, X, Zhang, H, Lai, L, Wang, X, Loera, S, Xue, L, He, H, Zhang, K, Hu, S, Huang, Y, Nelson, RA, Zhou, B, Zhou, L, Chu, P, Zhang, S, Zheng, S & Yen, Y 2013, 'Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers', Clinical Science, vol. 124, no. 9, pp. 567-578. https://doi.org/10.1042/CS20120240
Liu, Xiyong ; Zhang, Hang ; Lai, Lily ; Wang, Xiaochen ; Loera, Sofia ; Xue, Lijun ; He, Huiyin ; Zhang, Keqiang ; Hu, Shuya ; Huang, Yasheng ; Nelson, Rebecca A. ; Zhou, Bingsen ; Zhou, Lun ; Chu, Peiguo ; Zhang, Suzhan ; Zheng, Shu ; Yen, Yun. / Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. In: Clinical Science. 2013 ; Vol. 124, No. 9. pp. 567-578.
@article{b1243e7a3e304884b1b6a25934ee0e8d,
title = "Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers",
abstract = "The overexpression of RRM2 [RR (ribonucleotide reductase) small subunit M2] dramatically enhances the ability of the cancer cell to proliferate and to invade. To investigate further the relevance of RRM2 and CRCs (colorectal cancers), we correlated the expression of RRM2 with the clinical outcome of CRCs. A retrospective outcome study was conducted on CRCs collected from the COH [(City of Hope) National Medical Center, 217 cases] and ZJU (Zhejiang University, 220 cases). IHC (immunohistochemistry) was employed to determine the protein expression level of RRM2, and quantitative real-time PCR was employed to validate. Multivariate logistic analysis indicated that the adjusted ORs (odds ratios) of RRM2-high for distant metastases were 2.06 [95{\%} CI (confidence interval), 1.01-4.30] and 5.89 (95{\%} CI, 1.51-39.13) in the COH and ZJU sets respectively. The Kaplan-Meier analysis displayed that high expression of RRM2 had a negative impact on the OS (overall survival) and PFS (progress-free survival) of CRC in both sets significantly. The multivariate Cox analysis further demonstrated that HRs (hazard ratios) of RRM2-high for OS were 1.88 (95{\%} CI, 1.03-3.36) and 2.06 (95{\%} CI, 1.10-4.00) in the COH and ZJU sets respectively. Stratification analysis demonstrated that the HR of RRM2 dramatically increased to 12.22 (95{\%} CI, 1.62-258.31) in the MMR (mismatch repair) gene-deficient subgroup in the COH set. Meanwhile, a real-time study demonstrated that down-regulation of RRM2 by siRNA (small interfering RNA) could significantly and specifically reduce the cell growth and adhesion ability in HT-29 and HCT-8 cells. Therefore RRM2 is an independent prognostic factor and predicts poor survival of CRCs. It is also a potential predictor for identifying good responders to chemotherapy for CRCs.",
keywords = "Adenocarcinoma, Colon, Metastasis, Prognostic biomarker, Rectum, Ribonucleotide reductase, Survival",
author = "Xiyong Liu and Hang Zhang and Lily Lai and Xiaochen Wang and Sofia Loera and Lijun Xue and Huiyin He and Keqiang Zhang and Shuya Hu and Yasheng Huang and Nelson, {Rebecca A.} and Bingsen Zhou and Lun Zhou and Peiguo Chu and Suzhan Zhang and Shu Zheng and Yun Yen",
year = "2013",
month = "5",
day = "1",
doi = "10.1042/CS20120240",
language = "English",
volume = "124",
pages = "567--578",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "9",

}

TY - JOUR

T1 - Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers

AU - Liu, Xiyong

AU - Zhang, Hang

AU - Lai, Lily

AU - Wang, Xiaochen

AU - Loera, Sofia

AU - Xue, Lijun

AU - He, Huiyin

AU - Zhang, Keqiang

AU - Hu, Shuya

AU - Huang, Yasheng

AU - Nelson, Rebecca A.

AU - Zhou, Bingsen

AU - Zhou, Lun

AU - Chu, Peiguo

AU - Zhang, Suzhan

AU - Zheng, Shu

AU - Yen, Yun

PY - 2013/5/1

Y1 - 2013/5/1

N2 - The overexpression of RRM2 [RR (ribonucleotide reductase) small subunit M2] dramatically enhances the ability of the cancer cell to proliferate and to invade. To investigate further the relevance of RRM2 and CRCs (colorectal cancers), we correlated the expression of RRM2 with the clinical outcome of CRCs. A retrospective outcome study was conducted on CRCs collected from the COH [(City of Hope) National Medical Center, 217 cases] and ZJU (Zhejiang University, 220 cases). IHC (immunohistochemistry) was employed to determine the protein expression level of RRM2, and quantitative real-time PCR was employed to validate. Multivariate logistic analysis indicated that the adjusted ORs (odds ratios) of RRM2-high for distant metastases were 2.06 [95% CI (confidence interval), 1.01-4.30] and 5.89 (95% CI, 1.51-39.13) in the COH and ZJU sets respectively. The Kaplan-Meier analysis displayed that high expression of RRM2 had a negative impact on the OS (overall survival) and PFS (progress-free survival) of CRC in both sets significantly. The multivariate Cox analysis further demonstrated that HRs (hazard ratios) of RRM2-high for OS were 1.88 (95% CI, 1.03-3.36) and 2.06 (95% CI, 1.10-4.00) in the COH and ZJU sets respectively. Stratification analysis demonstrated that the HR of RRM2 dramatically increased to 12.22 (95% CI, 1.62-258.31) in the MMR (mismatch repair) gene-deficient subgroup in the COH set. Meanwhile, a real-time study demonstrated that down-regulation of RRM2 by siRNA (small interfering RNA) could significantly and specifically reduce the cell growth and adhesion ability in HT-29 and HCT-8 cells. Therefore RRM2 is an independent prognostic factor and predicts poor survival of CRCs. It is also a potential predictor for identifying good responders to chemotherapy for CRCs.

AB - The overexpression of RRM2 [RR (ribonucleotide reductase) small subunit M2] dramatically enhances the ability of the cancer cell to proliferate and to invade. To investigate further the relevance of RRM2 and CRCs (colorectal cancers), we correlated the expression of RRM2 with the clinical outcome of CRCs. A retrospective outcome study was conducted on CRCs collected from the COH [(City of Hope) National Medical Center, 217 cases] and ZJU (Zhejiang University, 220 cases). IHC (immunohistochemistry) was employed to determine the protein expression level of RRM2, and quantitative real-time PCR was employed to validate. Multivariate logistic analysis indicated that the adjusted ORs (odds ratios) of RRM2-high for distant metastases were 2.06 [95% CI (confidence interval), 1.01-4.30] and 5.89 (95% CI, 1.51-39.13) in the COH and ZJU sets respectively. The Kaplan-Meier analysis displayed that high expression of RRM2 had a negative impact on the OS (overall survival) and PFS (progress-free survival) of CRC in both sets significantly. The multivariate Cox analysis further demonstrated that HRs (hazard ratios) of RRM2-high for OS were 1.88 (95% CI, 1.03-3.36) and 2.06 (95% CI, 1.10-4.00) in the COH and ZJU sets respectively. Stratification analysis demonstrated that the HR of RRM2 dramatically increased to 12.22 (95% CI, 1.62-258.31) in the MMR (mismatch repair) gene-deficient subgroup in the COH set. Meanwhile, a real-time study demonstrated that down-regulation of RRM2 by siRNA (small interfering RNA) could significantly and specifically reduce the cell growth and adhesion ability in HT-29 and HCT-8 cells. Therefore RRM2 is an independent prognostic factor and predicts poor survival of CRCs. It is also a potential predictor for identifying good responders to chemotherapy for CRCs.

KW - Adenocarcinoma

KW - Colon

KW - Metastasis

KW - Prognostic biomarker

KW - Rectum

KW - Ribonucleotide reductase

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84874754759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874754759&partnerID=8YFLogxK

U2 - 10.1042/CS20120240

DO - 10.1042/CS20120240

M3 - Article

VL - 124

SP - 567

EP - 578

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 9

ER -